FIRALIS S.A.
Created in 2008
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
39 141 2,579Activities
Technologies
Entity types
Location
35 Rue du Fort, 68330 Huningue, France
Huningue
France
Employees
Scale: 11-50
Estimated: 32
SIREN
504944364Engaged corporates
19
4 5Added in Motherbase
6 years, 2 months ago
biotech Value proposition
Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM).
1) BIOMARKER PRODUCTS
Firalis develops BM-based diagnostic, prognostic and theranostic tools:
● RUO Kits (Research-Use-Only), based on validated innovative biomarkers
● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers
2) BIOMARKER R&D
● Development of proprietary BMs
- Cardiovascular, Inflammatory, Autoimmune and Neurology
● Drug Safety & Drug Efficacy
● Patient Stratification
● Personalized Medicine
3) BIOMARKER-RELATED CRO SERVICES
BM Discovery for laboratories, biotechs and pharmaceutical industry:
- Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200TM, Meso Scale Discovery®, Singulex Erenna®, Protein Simple EllaTM, Olink and Siemens Dimension® EXLTM 200)
- Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.)
- Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery
- Assay development and validation on various platforms, development of critical reagents (antibodies and proteins)
- Biobanking and sample repository services supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)
- Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP))
For more information please visit our website.
BIOMARKERS, CARDIOVASCULAR BIOMARKERS, DRUG-INDUCED VASCULAR SAFETY, DIAGNOSTIC KITS, BIOMARKER SERVICES, BIOMARKER ASSAY DEVELOPMENT, IN-VITRO DIAGNOSTICS, SAFETY BIOMARKERS, INFLAMMATORY, PROGNOSTIC KITS, BIOMARKERS TESTING, NEXT GENERATION SEQUENCING (NGS), Alzheimer, Immunoassay, Rheumatoid Arthritis, Acute Myocardial Infarction, Olink, HTG Molecular Diagnostics, CRO, Clinical Research Organization, Illumina, Next Generation Sequencing, NGS, qPCR, ELISA, Luminex, MSD, Protein Simple, Flow Cytometry, Assay development, clinical validation, central lab, bioanalysis, bioanalytical service, and precision medicineOriginal language
Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM).
1) BIOMARKER PRODUCTS
Firalis develops BM-based diagnostic, prognostic and theranostic tools:
● RUO Kits (Research-Use-Only), based on validated innovative biomarkers
● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers
2) BIOMARKER R&D
● Development of proprietary BMs
- Cardiovascular, Inflammatory, Autoimmune and Neurology
● Drug Safety & Drug Efficacy
● Patient Stratification
● Personalized Medicine
3) BIOMARKER-RELATED CRO SERVICES
BM Discovery for laboratories, biotechs and pharmaceutical industry:
- Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200TM, Meso Scale Discovery®, Singulex Erenna®, Protein Simple EllaTM, Olink and Siemens Dimension® EXLTM 200)
- Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.)
- Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery
- Assay development and validation on various platforms, development of critical reagents (antibodies and proteins)
- Biobanking and sample repository services supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)
- Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP))
For more information please visit our website.
Firalis - GROUP HOME
https://www.firalis.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 26 Nov 2024 | | |
 Daiichi Sankyo Pharmaceutical | Daiichi Sankyo Pharmaceutical | Other 14 Oct 2024 | | |
 Elanco Animal Health | Elanco Animal Health | Other 14 Oct 2024 | | |
 Grand E-Nov+, l'Agence régionale des transformations Consulting, Business Consulting and Services | Grand E-Nov+, l'Agence régionale des transformations Consulting, Business Consulting and Services | Other 14 Oct 2024 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 14 Oct 2024 | | |
 Novartis Pharmaceutical, Pharmaceutical Manufacturing | Novartis Pharmaceutical, Pharmaceutical Manufacturing | Other 14 Oct 2024 | | |
 France Travail Human ressources, Government Administration | France Travail Human ressources, Government Administration | Other 14 Oct 2024 | | |
 Inria Research, Research Services | Inria Research, Research Services | Other 25 Sep 2024 | | |
 CIC Bank, Banking | CIC Bank, Banking | Other 28 Nov 2023 | | |
 SATT CONECTUS Research, Research Services | SATT CONECTUS Research, Research Services | Other 28 Nov 2023 | | |